GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for ACTIVE W

ACTIVE W

Official Title

Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events

Status

Completed

Overview

To determine the efficacy (noninferiority) of clopidogrel plus ASA versus an other oral anticoagulation in patients with AF and at least 1 risk factor for stroke.

Study Design

Randomized, double-blind, efficacy study, placebo controlled non-inferiority trial.

Primary Endpoint

Composite outcome of stroke, non-CNS systemic embolism, myocardial infarction or vascular death

Number of Patients

6507

Number of Sites

639

Number of Countries

33

Study Period

2003–2005

Principal Investigator

Stuart Connolly

Program Manager

Susan Chrolavicius

Research Coordinator

Heather Beresh, Laura Bonilla

Key Publications

  • ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367(9526):1903-12.